SANA BIOTECHNO. DL -,0001

Sana Biotechnology confirmed that an abstract with preclinical data on its in‑vivo CAR‑T product candidate SG293 was accepted for an oral presentation at the ASGCT annual meeting on May 12, 2026. SG293 uses fusogen‑based delivery and specifically targets CD8+ T cells to generate CD19‑directed CAR‑T cells, while aiming to avoid delivery to other tissues such as the liver. The company plans to further investigate SG293 in B‑cell cancers and B‑cell‑mediated autoimmune diseases. » More on de.investing.com

Sana Biotechnology reports 14‑month follow‑up data from a first‑in‑human study in which a type 1 diabetes patient received HIP‑modified allogeneic islet cells (UP421) transplanted without immunosuppression. C‑peptide levels indicate sustained survival and functional insulin responses after meals; no safety issues were reported and a PET‑MRI at 52 weeks localized islet cells at the transplant site. The company recorded negative free cash flow of USD 145 million over the past twelve months, its stock trades well below analyst targets, and Sana plans to file an IND this year for the stem‑cell therapy SC451. » More on de.investing.com

Bernard J. Cassidy will resign from his roles as executive vice president, chief legal officer and corporate secretary effective October 20, 2025, and is retiring for personal reasons. Sana said Cassidy will remain available to the company in an advisory capacity during a transition period. Aaron M. Grossman is slated to assume the positions of executive vice president and chief legal officer effective October 20, 2025. » More on de.investing.com